Benzinga's Top Ratings Upgrades, Downgrades For July 3, 2023

Upgrades

For Lazard Ltd LAZ, Wolfe Research upgraded the previous rating of Underperform to Peer Perform. Lazard earned $0.26 in the first quarter, compared to $1.05 in the year-ago quarter. The current stock performance of Lazard shows a 52-week-high of $43.44 and a 52-week-low of $27.71. Moreover, at the end of the last trading period, the closing price was at $32.00.

Jefferies upgraded the previous rating for ACM Research Inc ACMR from Underperform to Buy. ACM Research earned $0.15 in the first quarter, compared to $0.01 in the year-ago quarter. At the moment, the stock has a 52-week-high of $20.01 and a 52-week-low of $5.46. ACM Research closed at $13.08 at the end of the last trading period.

See all analyst ratings upgrades.

Downgrades

See all analyst ratings downgrades.

Initiations

B of A Securities initiated coverage on Reneo Pharmaceuticals Inc RPHM with a Buy rating. The price target for Reneo Pharmaceuticals is set to $23.00. In the first quarter, Reneo Pharmaceuticals showed an EPS of $0.60, compared to $0.53 from the year-ago quarter. The current stock performance of Reneo Pharmaceuticals shows a 52-week-high of $11.29 and a 52-week-low of $1.79. Moreover, at the end of the last trading period, the closing price was at $6.56.

With a Buy rating, HC Wainwright & Co. initiated coverage on LifeMD Inc LFMD. The price target seems to have been set at $9.00 for LifeMD. For the first quarter, LifeMD had an EPS of $0.06, compared to year-ago quarter EPS of $0.25. The stock has a 52-week-high of $4.41 and a 52-week-low of $1.14. At the end of the last trading period, LifeMD closed at $4.35.

HC Wainwright & Co. initiated coverage on Ensysce Biosciences Inc ENSC with a Buy rating. The price target for Ensysce Biosciences is set to $9.00. In the first quarter, Ensysce Biosciences showed an EPS of $2.08, compared to $14.66 from the year-ago quarter. The stock has a 52-week-high of $220.80 and a 52-week-low of $1.75. At the end of the last trading period, Ensysce Biosciences closed at $1.80.

With a Buy rating, DBS Bank initiated coverage on Amazon.com Inc AMZN. The price target seems to have been set at $150.00 for Amazon.com. Amazon.com earned $0.35 in the first quarter, compared to $0.37 in the year-ago quarter. The stock has a 52-week-high of $146.57 and a 52-week-low of $81.43. At the end of the last trading period, Amazon.com closed at $130.36.

See all analyst ratings initiations.